Orthofix Q1 net sales $175.2M (+65% reported, +12% pro forma CC); GAAP EPS $(1.71), adj. EPS $(0.10)

Orthofix Medical Inc.

2023-Q1 EPS reported -$1.71 revenue$175,204,000

Net loss of $60.9M vs. $4.5M loss prior year; adjusted net loss $3.6M vs. adj. net income $1.0M.
U.S. spinal implant pro forma sales +18% YoY; Bone Growth Therapies +14%; Global Orthopedics +13.6% CC.
Full commercial launch of Lattus Lateral Access System and Fathom Pedicle Retractor System announced.
FY 2023 net sales guidance raised to $750-756M (from $743-753M); adj. EBITDA expected $40-45M.
Cash $50.0M; $45M drawn on $300M revolver; free cash flow $(45.9)M for Q1.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

Orthofix Medical Inc. reported the quarter ended March 31, 2023 results: revenue $175.2 million, net income $(60.9) million, or $(1.71) per share, EPS $(1.71).

Period: the quarter ended March 31, 2023
Revenue: $175.2 million
Net income: $(60.9) million, or $(1.71) per share
EPS: $(1.71)
Result: reported results

Exact text from the filing

and certain related legal expenses, which are recorded as general and a --- EX-99 (EX-99.1) --- EX-99 Exhibit 99.1 Orthofix Reports First Quarter 2023 Results • Net sales of $175.2 million, an increase of 65% on a reported basis and 12% on a pro forma constant currency basis over prior year • Bone Growth Therapies growth of 14%, with growth coming from both spine

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.8

Orthofix Medical Inc. reported the year ended December 31, 2023 results: revenue $750 to $756. Guidance reaffirmed.

Period: the year ended December 31, 2023
Revenue: $750 to $756
Guidance: reaffirmed
Result: guidance update

Exact text from the filing

changes that may occur this year. Current 2023 Outlook Previous 2023 Outlook (Unaudited, U.S. Dollars, in millions, except per share data) Low High Low High Full year net sales $ 750 1 $ 756 1 $ 743 $ 753 Full year adjusted EBITDA $ 40 $ 45 N/A N/A 1 Represents a year-over-year increase of 62.8% to 64.1% on a reported basis and an increase of 7.0% to 7.9% on a

View on SEC.gov

10 earnings releases filed in the last 30 days. Browse all earnings releases →

Orthofix Medical Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-019696

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.